{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T12:52:47Z","timestamp":1794833567241,"version":"4.9.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017556","name":"Marie-Jos\u00e9e and Henry R. Kravis Center for Molecular Oncology","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100017556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019402","name":"Puma Biotechnology","doi-asserted-by":"publisher","award":["CA 90024"],"award-info":[{"award-number":["CA 90024"]}],"id":[{"id":"10.13039\/100019402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ygyno.2023.12.004","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T03:59:06Z","timestamp":1704945546000},"page":"162-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial"],"prefix":"10.1016","volume":"181","author":[{"given":"Claire F.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anishka","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bello Roufai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Tinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Melisko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iben","family":"Spanggaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"ElNaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Panni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee L.","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"DiPrimeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa D.","family":"Eli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Solit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.12.004_bb0005","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0010","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0015","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000279","article-title":"Activating HER2 mutations as emerging targets in multiple solid cancers","volume":"2","author":"Connell","year":"2017","journal-title":"ESMO Open."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ygyno.2017.12.023","article-title":"ERBB2 mutation: a promising target in non-squamous cervical cancer","volume":"148","author":"Xiang","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0035","doi-asserted-by":"crossref","first-page":"22730","DOI":"10.1073\/pnas.1911385116","article-title":"Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy","volume":"116","author":"Zammataro","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0040","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2016.0237","article-title":"Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial","volume":"2","author":"Awada","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","article-title":"Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial","volume":"21","author":"Chan","year":"2021","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ygyno.2023.12.004_bb0050","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0055","doi-asserted-by":"crossref","first-page":"PS4-13","DOI":"10.1158\/1538-7445.SABCS20-PS4-13","article-title":"Abstract PS4-13: irreversible inhibition of HER2 activating mutations with neratinib enhances the pre-clinical efficacy of trastuzumab emtansine and trastuzumab deruxtecan","volume":"81","author":"Bose","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0060","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/2159-8290.CD-14-1211","article-title":"HER2 activating mutations are targets for colorectal cancer treatment","volume":"5","author":"Kavuri","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0065","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","article-title":"Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase","volume":"64","author":"Rabindran","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0070","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1038\/s41467-020-15885-7","article-title":"Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0075","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2020.07.025","article-title":"Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial","volume":"159","author":"Oaknin","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.12.004_bb0085","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0095","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1038\/s41467-021-24109-5","article-title":"Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS","volume":"12","author":"Rose Brannon","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0100","series-title":"Cervical Squamous Cell Carcinoma","author":"cBioPortal for Cancer Genomics","year":"2018"},{"key":"10.1016\/j.ygyno.2023.12.004_bb0105","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: powering precision medicine through an international consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0110","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-19-1658","article-title":"Impact of FDG PET imaging for expanding patient eligibility and measuring treatment response in a genome-driven basket trial of the pan-HER kinase inhibitor, neratinib","volume":"25","author":"Ulaner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0115","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1200\/JCO.2021.39.3_suppl.9","article-title":"Safety and efficacy of anti\u2013PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study","volume":"39","author":"Andre","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0125","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0130","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0140","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/2159-8290.CD-19-0966","article-title":"Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer","volume":"10","author":"Smyth","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0145","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1158\/1078-0432.CCR-15-3036","article-title":"Dual characteristics of novel HER2 kinase domain mutations in response to hER2-targeted therapies in human breast cancer","volume":"22","author":"Zuo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0150","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0155","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1073\/pnas.1203201109","article-title":"Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2","volume":"109","author":"Greulich","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0160","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.clbc.2016.08.001","article-title":"A rare case of S310F somatic ERBB2 mutation in a HER2-nonamplified breast cancer","volume":"17","author":"Jasra","year":"2017","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ygyno.2023.12.004_bb0165","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103074","article-title":"A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy","volume":"62","author":"Li","year":"2020","journal-title":"EBioMedicine."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/gyno.2000.5826","article-title":"The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study","volume":"78","author":"Smith","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0180","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/ijgc-2022-003728","article-title":"The increasing incidence of stage IV cervical cancer in the USA: what factors are related?","volume":"32","author":"Francoeur","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2023.12.004_bb0185","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ygyno.2022.10.003","article-title":"Gastric-type adenocarcinoma of the cervix: clinical outcomes and genomic drivers","volume":"167","author":"Ehmann","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0190","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/PAS.0000000000000532","article-title":"Gastric-type endocervical adenocarcinoma: an aggressive tumor with unusual metastatic patterns and poor prognosis","volume":"39","author":"Karamurzin","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010170","article-title":"Gastric-type adenocarcinoma of the uterine cervix associated with poor response to definitive radiotherapy","volume":"15","author":"Kuruma","year":"2022","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2023.12.004_bb0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/igc.0000000000001145","article-title":"Chemoresistance of gastric-type mucinous carcinoma of the uterine cervix: a study of the sankai gynecology study group","volume":"28","author":"Kojima","year":"2018","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823016013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823016013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:03:04Z","timestamp":1778634184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823016013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":40,"alternative-id":["S0090825823016013"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.12.004","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}